FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $109,726 | -62.6% | 33,453 | -16.3% | 0.00% | – |
Q1 2024 | $293,468 | +107.4% | 39,982 | +5.7% | 0.00% | – |
Q4 2023 | $141,466 | +49.2% | 37,825 | -15.4% | 0.00% | – |
Q3 2023 | $94,804 | -91.9% | 44,719 | -81.8% | 0.00% | -100.0% |
Q2 2023 | $1,168,247 | +238.7% | 245,430 | +305.6% | 0.00% | – |
Q1 2023 | $344,895 | -85.4% | 60,508 | -74.1% | 0.00% | -100.0% |
Q4 2022 | $2,357,811 | -52.8% | 233,678 | +4.8% | 0.00% | -66.7% |
Q3 2022 | $4,997,000 | +46.1% | 223,004 | +61.5% | 0.00% | +50.0% |
Q2 2022 | $3,421,000 | -40.7% | 138,089 | -7.2% | 0.00% | -33.3% |
Q1 2022 | $5,770,000 | -35.3% | 148,834 | -2.4% | 0.00% | -25.0% |
Q4 2021 | $8,921,000 | -81.4% | 152,462 | -81.1% | 0.00% | -82.6% |
Q3 2021 | $47,926,000 | -30.3% | 808,610 | +2.1% | 0.02% | -30.3% |
Q2 2021 | $68,742,000 | +387.4% | 792,061 | +363.0% | 0.03% | +312.5% |
Q1 2021 | $14,105,000 | +166.8% | 171,062 | +194.3% | 0.01% | +166.7% |
Q4 2020 | $5,286,000 | -8.8% | 58,132 | -59.9% | 0.00% | -25.0% |
Q3 2020 | $5,797,000 | -50.3% | 145,019 | -57.3% | 0.00% | -55.6% |
Q2 2020 | $11,653,000 | +630.6% | 339,641 | +372.9% | 0.01% | +800.0% |
Q1 2020 | $1,595,000 | +262.5% | 71,816 | +218.7% | 0.00% | – |
Q4 2019 | $440,000 | +57.1% | 22,533 | +24.6% | 0.00% | – |
Q3 2019 | $280,000 | -36.7% | 18,089 | -17.2% | 0.00% | – |
Q2 2019 | $442,000 | -79.3% | 21,848 | -82.0% | 0.00% | -100.0% |
Q1 2019 | $2,136,000 | +522.7% | 121,640 | +352.5% | 0.00% | – |
Q4 2018 | $343,000 | -93.9% | 26,881 | -92.2% | 0.00% | -100.0% |
Q3 2018 | $5,617,000 | +181.0% | 344,997 | +95.6% | 0.00% | +100.0% |
Q2 2018 | $1,999,000 | +214.8% | 176,384 | +170.2% | 0.00% | – |
Q1 2018 | $635,000 | +20.5% | 65,287 | -24.6% | 0.00% | – |
Q4 2017 | $527,000 | +281.9% | 86,531 | +146.5% | 0.00% | – |
Q3 2017 | $138,000 | -2.1% | 35,098 | -20.1% | 0.00% | – |
Q2 2017 | $141,000 | +370.0% | 43,925 | +146.9% | 0.00% | – |
Q2 2016 | $30,000 | -61.5% | 17,792 | -59.1% | 0.00% | – |
Q1 2016 | $78,000 | +271.4% | 43,455 | +571.6% | 0.00% | – |
Q4 2015 | $21,000 | -71.2% | 6,470 | -53.1% | 0.00% | – |
Q3 2015 | $73,000 | -56.0% | 13,800 | -46.6% | 0.00% | – |
Q2 2015 | $166,000 | +130.6% | 25,842 | +75.0% | 0.00% | – |
Q1 2015 | $72,000 | -53.2% | 14,770 | -52.0% | 0.00% | – |
Q4 2014 | $154,000 | +14.1% | 30,796 | +15.4% | 0.00% | – |
Q3 2014 | $135,000 | -12.3% | 26,683 | +8.0% | 0.00% | – |
Q2 2014 | $154,000 | -6.1% | 24,701 | +46.1% | 0.00% | – |
Q1 2014 | $164,000 | +42.6% | 16,905 | -8.6% | 0.00% | – |
Q4 2013 | $115,000 | – | 18,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |